Literature DB >> 7334462

Variability in derived parameters of furosemide pharmacokinetics.

P Chennavasin, R A Johnson, D C Brater.   

Abstract

The pharmacokinetics of furosemide in normal man reported from a number of investigators show great discrepancies. We have evaluated the effect on derived pharmacokinetic parameters of furosemide of using different weighting factors or fewer data points to fit the same set of data to an exponential equation, or using noncompartmental analysis. Terminal half-lives of furosemide differed vastly, as did the volume of distribution, but to a lesser extent. The plasma clearance was rather consistent with the different methods used. Thus the discrepancies of the pharmacokinetics of furosemide may, in large part, be due to different methods of analysis of the data. The terminal half-life was most subject to errors of method and the plasma clearance the least.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7334462     DOI: 10.1007/bf01061029

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  29 in total

1.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

2.  The effect of assay methods on plasma levels and pharmacokinetics of theophylline: HPLC and EIA.

Authors:  T Ishizaki; M Watanabe; N Morishita
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

Review 3.  Use of statistical methods in evaluation of in vivo performance of dosage forms.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1973-10       Impact factor: 3.534

4.  Methaqualone pharmacokinetics after single- and multiple-dose administration in man.

Authors:  R K Nayak; R D Smyth; J H Chamberlain; A Polk; A F DeLong; T Herczeg; P B Chemburkar; R S Joslin; N H Reavey-Cantwell
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

5.  Pharmacokinetics of orally administered furosemide.

Authors:  M R Kelly; R E Cutler; A W Forrey; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

6.  Curve fitting and modeling in pharmacokinetics.

Authors:  K T Muir; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1979-12

7.  Pharmacokinetics--uses and abuses.

Authors:  P J Fell; M T Stevens
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

8.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

9.  Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man.

Authors:  P Chennavasin; R Seiwell; D C Brater
Journal:  J Pharmacol Exp Ther       Date:  1980-10       Impact factor: 4.030

10.  Furosemide kinetics in renal failure.

Authors:  W J Tilstone; A Fine
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

View more
  10 in total

Review 1.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

2.  The effects of the method of calculation on the evaluation of the pharmacokinetic parameters of oxytetracycline after intravenous administration to calves.

Authors:  J O Errecalde; N Mestorino; E L Mariño
Journal:  Vet Res Commun       Date:  1997-05       Impact factor: 2.459

Review 3.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 4.  Current models in pharmacokinetics: applications in veterinary pharmacology.

Authors:  L D Kinabo; Q A McKellar
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

5.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

6.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

7.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.

Authors:  W R Gillespie; P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1985-08

8.  High-pressure liquid chromatographic assay and pharmacokinetics of HR 810 after intramuscular injection in rabbits.

Authors:  R E Bawdon; Y S Lu; D C Brater
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

9.  Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.

Authors:  O Schuster; D Loew; H E Knoell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

Review 10.  Nomograms for drug use in renal disease.

Authors:  P Chennavasin; D C Brater
Journal:  Clin Pharmacokinet       Date:  1981 May-Jun       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.